Abstract
We describe a patient with rheumatoid vasculitis (RV) who showed a good response to anti-tumor necrosis factor-a therapy. TNF-a antagonists should be considered as treatment in systemic RV, especially in patients who do not respond to immunosuppressive drugs or who have contraindication for such treatment.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antibodies, Monoclonal / therapeutic use*
-
Antirheumatic Agents / therapeutic use*
-
Humans
-
Infliximab
-
Male
-
Rheumatic Diseases / complications
-
Rheumatic Diseases / drug therapy*
-
Rheumatic Diseases / pathology
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Vasculitis / drug therapy*
-
Vasculitis / etiology
-
Vasculitis / pathology
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Tumor Necrosis Factor-alpha
-
Infliximab